<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Infect Chemother</journal-id><journal-id journal-id-type="publisher-id">IC</journal-id><journal-title-group><journal-title>Infection &#x00026; Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">2093-2340</issn><issn pub-type="epub">2092-6448</issn><publisher><publisher-name>The Korean Society of Infectious Diseases and Korean Society for Chemotherapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7533207</article-id><article-id pub-id-type="pmid">32989938</article-id><article-id pub-id-type="doi">10.3947/ic.2020.52.3.307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Convalescent Plasma Therapy for Coronavirus Disease 2019</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2775-3315</contrib-id><name><surname>Choi</surname><given-names>Jun Yong</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, <country>Korea</country>.</aff><author-notes><corresp>Corresponding Author: Jun Yong Choi, MD, PhD. Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: +82-2-2228-1974, Fax: +82-2-393-6884, <email>seran@yuhs.ac</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>03</day><month>9</month><year>2020</year></pub-date><volume>52</volume><issue>3</issue><fpage>307</fpage><lpage>316</lpage><history><date date-type="received"><day>07</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Convalescent plasma has been used for decades to prevent and treat a wide range of infectious diseases for which no specific treatment is available. The use of convalescent plasma involves transfusing plasma collected from patients who have recovered from a viral illness, in an attempt to transfer virus-neutralizing antibodies and confer passive immunity. In addition to the antiviral mechanisms of neutralizing antibodies, the immunomodulatory effects of plasma components could have benefits. Several small and large-scale studies have shown the effects of convalescent plasma for the treatment of severe coronavirus disease 2019 (COVID-19). In addition to transfusion-related side effects, unexpected side effects such as antibody-dependent enhancement (ADE) may occur during convalescent plasma therapy, but early safety studies have not found any cases of ADE among more than 5,000 participants. With historical precedents and recent clinical studies, convalescent plasma therapy should be considered as a candidate therapy for COVID-19 given the limited effectiveness of antiviral drugs and lack of a vaccine. A system to secure safe collection and use of convalescent plasma should be developed as a response to the pandemic. Further clinical trials should be conducted to determine the safety and efficacy of convalescent plasma therapy concurrently with its clinical use.</p></abstract><kwd-group kwd-group-type="author"><kwd>Coronavirus disease 2019</kwd><kwd>Severe acute respiratory syndrome coronavirus 2</kwd><kwd>COVID-19 serotherapy</kwd><kwd>Plasma</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global concern, and the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a Public Health Emergency of International Concern on January 30, 2020, and a pandemic on March 11, 2020 [<xref rid="B1" ref-type="bibr">1</xref>]. Between December 31, 2019 and July 29, 2020, more than 16 million cases of COVID-19 were reported worldwide, including more than 660,000 deaths. Most patients with COVID-19 have mild disease and recover without any treatment. However, older individuals with comorbidities such as diabetes mellitus, hypertension, and respiratory or cardiovascular disease are at greater risk of complications and mortality [<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref>].</p><p>To overcome the COVID-19 pandemic, the development of effective therapeutic agents and vaccines is crucial. However, as of August 3, 2020, there are few therapeutic agents that have been approved for the treatment of COVID-19, and there are no vaccines [<xref rid="B4" ref-type="bibr">4</xref>]. Remdesivir is the only antiviral agent that showed efficacy in a randomized controlled trial [<xref rid="B5" ref-type="bibr">5</xref>], and dexamethasone is another medication that showed efficacy in severe COVID-19 patients [<xref rid="B6" ref-type="bibr">6</xref>]. However, having these medications is not enough to overcome the COVID-19 pandemic. Given the lack of therapeutic options for COVID-19 and vaccines, historical interventions for emerging infectious diseases have remerged as options for disease control. Given its rapid acquisition, convalescent plasma therapy has been considered as an emergency intervention in several pandemics, including the Spanish flu, severe acute respiratory syndrome coronavirus (SARS-CoV-1), and West Nile virus, and more recently, Ebola virus [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>].</p><p>During the current COVID-19 pandemic, multiple studies of varying sizes have been conducted on convalescent plasma therapy for COVID-19. The purpose of this review is to provide the theoretical rationale, summarize the evidence of safety and effectiveness, and discuss considerations for clinical application of convalescent plasma therapy.</p></sec><sec sec-type="other1"><title>Historical precedents</title><p>In the early twentieth century, convalescent sera were used to stem epidemics of viral diseases such as poliomyelitis, measles, mumps, and influenza [<xref rid="B10" ref-type="bibr">10</xref>]. A retrospective meta-analysis of eight studies on the use of convalescent sera involving 1703 patients during the 1918 H1N1 influenza virus pandemic suggested that those who received serum had lower mortality [<xref rid="B11" ref-type="bibr">11</xref>]. During the 2009 - 2010 H1N1 influenza pandemic, convalescent plasma was used to treat patients with severe H1N1 infection requiring critical care [<xref rid="B12" ref-type="bibr">12</xref>]. A study with 93 participants showed that treatment of severe H1N1 2009 infection with convalescent plasma reduced respiratory tract viral load, serum cytokine response, and mortality. During the 2013 Ebola epidemic in West Africa, a nonrandomized study showed significantly longer survival for those treated with convalescent whole blood compared to those who received standard treatment [<xref rid="B13" ref-type="bibr">13</xref>]. However, another nonrandomized study on Ebola virus disease did not show the survival benefit of convalescent plasma therapy [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Convalescent plasma therapy has also been used for treating coronavirus diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A study from a hospital in Hong Kong evaluated the efficacy of convalescent plasma therapy in the treatment of patients with SARS in 2003 [<xref rid="B15" ref-type="bibr">15</xref>]. A higher day-22 discharge rate was observed among patients who were given convalescent plasma before Day 14 of illness and among those who were PCR positive and seronegative for coronavirus at the time of plasma infusion. During the MERS epidemic in South Korea, convalescent plasma therapy was performed for several MERS patients, and a study suggested that donor plasma with a neutralization activity of a plaque reduction neutralization test (PRNT) titer &#x02265;1:80 should be used for convalescent plasma therapy [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Although large-scale randomized controlled trials have not yet been performed, and most studies did not evaluate neutralizing activities of used convalescent plasma, previous experiences on convalescent plasma therapy for the treatment of emerging infectious diseases provide us with important historical precedents that this intervention might be useful for confronting the COVID-19 epidemics.</p></sec><sec sec-type="other2"><title>Possible mechanism of action</title><p>Convalescent plasma therapy is a passive antibody therapy that involves the administration of antibodies against a given pathogen to a susceptible individual for the purpose of preventing or treating an infectious disease. Neutralizing antibodies have been considered essential in the effects of convalescent plasma therapy, and the efficacy of this therapy was associated with the titer of neutralizing antibodies in the convalescent plasma [<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">18</xref>]. In addition to the antiviral mechanisms of neutralizing antibodies, immunomodulatory effects of plasma components could have additional benefits [<xref rid="B18" ref-type="bibr">18</xref>]. During apheresis, in addition to neutralizing antibodies, other proteins such as anti-inflammatory cytokines, clotting factors, natural antibodies, defensins, pentraxins, and other undefined proteins are obtained from donors [<xref rid="B19" ref-type="bibr">19</xref>]. In this sense, transfusion of convalescent plasma in infected patients may provide further benefits such as immunomodulation via amelioration of severe inflammatory response.</p></sec><sec sec-type="other3"><title>Clinical studies on COVID-19</title><p>Several uncontrolled case series of convalescent plasma therapy for the treatment of patients with COVID-19 have suggested a possible benefit [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref>]. Multiple studies have evaluated the effects of convalescent plasma therapy for patients with COVID-19 (<xref rid="T1" ref-type="table">Table 1</xref>) [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B23" ref-type="bibr">23</xref><xref rid="B24" ref-type="bibr">24</xref><xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">26</xref><xref rid="B27" ref-type="bibr">27</xref>]. The reports showed that convalescent plasma therapy induced reduction in viral loads and improvement of laboratory markers and clinical signs. Most studies were non-randomized, non-controlled studies, and the participants had severe or life-threatening disease. Given encouraging historical precedents and the lack of proven effective therapy for COVID-19, clinical studies on the use of convalescent plasma as a treatment option for COVID-19 are ongoing in many countries. As of August 3 2020, a total of 132 studies evaluating the role of convalescent plasma in COVID-19 are registered on ClinicalTrials.gov. The first randomized trial of convalescent plasma therapy for COVID-19 patients was conducted in China [<xref rid="B28" ref-type="bibr">28</xref>]. To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19, an open-label, multicenter, randomized clinical trial was performed in seven medical centers in Wuhan, China. The study included 103 participants with severe or life-threatening COVID-19. To ensure the therapeutic potency of the convalescent plasma, only the plasma units with a spike protein receptor-binding domain (S-RBD)-specific immunoglobulin G (IgG) titer of at least 1:640 were used in the study. However, because the COVID-19 epidemic in China was contained while enrolment was in progress, the trial was terminated before it reached its targeted sample size of 200 patients. Hence, it was underpowered and many comparisons between the convalescent plasma group and the control group were not statistically significant. The primary endpoint of time to clinical improvement within 28 days (defined as being discharged alive or having a reduction of 2 points on a 6-point disease severity scale) was 2.15 days shorter (95% confidence interval [CI], &#x02212;5.28 to 0.99 days; hazard ratio [HR]: 1.40, 95% CI: 0.79 - 2.49; <italic>P</italic> = 0.26) in the intervention group compared to the control group, and 27 (51.9%) patients in the intervention group experienced a clinical improvement within 28 days, compared to 22 patients (43.1%) in the control group (difference: 8.8%; 95% CI: &#x02212;10.4% to 28%; odds ratio [OR]: 1.20, 95% CI:0.80 - 1.81; <italic>P</italic> = 0.37). In analyses stratified by disease severity, among patients with severe disease (23 in the convalescent plasma group and 22 in the control group), the time to clinical improvement was 4.94 days shorter (95% CI: &#x02212;9.33 to &#x02212;0.54 days; HR: 2.15, 95% CI: 1.07 - 4.32; <italic>P</italic> = 0.03, <italic>P</italic> = 0.03) in the intervention group, and clinical improvement at 28 days occurred in 21 patients (91.3%) in the intervention group <italic>vs.</italic> 15 patients (68.2%) in the control group (OR:1.34, 95% CI: 0.98 - 1.83; <italic>P</italic> = 0.07). Although the study was underpowered, the study results showed convalescent plasma therapy was associated with some clinical improvement in severely ill patients, but not in critically ill patients. Because antibody therapies generally work when administered earlier stage of disease, the efficacy might be better in patients with severe (respiratory distress and/or hypoxemia) than life-threatening (shock, organ failure, or requiring mechanical ventilation). Some of the patients with life-threatening disease might have had irreversible disease at the time that plasma therapy was initiated.</p><table-wrap id="T1" orientation="portrait" position="float"><?Table Large?><label>Table 1</label><caption><title>Studies of convalescent plasma therapy for treating COVID-19</title></caption><alternatives><graphic xlink:href="ic-52-307-i001"/><table frame="hsides" rules="rows"><col width="15.38%" span="1"/><col width="7.35%" span="1"/><col width="15.38%" span="1"/><col width="8.03%" span="1"/><col width="8.03%" span="1"/><col width="11.62%" span="1"/><col width="11.62%" span="1"/><col width="15.38%" span="1"/><col width="7.18%" span="1"/><thead><tr><th valign="top" align="left" rowspan="2" colspan="1" style="background-color:rgb(227,223,239)">Authors, Year of publication</th><th valign="top" align="center" rowspan="2" colspan="1" style="background-color:rgb(227,223,239)">Country</th><th valign="top" align="center" rowspan="2" colspan="1" style="background-color:rgb(227,223,239)">Study design</th><th valign="top" align="center" rowspan="1" colspan="2" style="background-color:rgb(227,223,239)">Number of participants</th><th valign="top" align="center" rowspan="1" colspan="2" style="background-color:rgb(227,223,239)">Clinical outcomes</th><th valign="top" align="center" rowspan="2" colspan="1" style="background-color:rgb(227,223,239)">Adverse events</th><th valign="top" align="center" rowspan="2" colspan="1" style="background-color:rgb(227,223,239)">Reference</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Cases</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Controls</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Cases</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Controls</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Abolghasemi et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1">Iran</td><td valign="top" align="center" rowspan="1" colspan="1">Nonrandomized, controlled study</td><td valign="top" align="center" rowspan="1" colspan="1">115</td><td valign="top" align="center" rowspan="1" colspan="1">74</td><td valign="top" align="center" rowspan="1" colspan="1">14.8% died</td><td valign="top" align="center" rowspan="1" colspan="1">24.3% died</td><td valign="top" align="center" rowspan="1" colspan="1">Not reported</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B27" ref-type="bibr">27</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Ahn et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Korea</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">100% improved</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">None</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">[<xref rid="B23" ref-type="bibr">23</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duan et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1">China</td><td valign="top" align="center" rowspan="1" colspan="1">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100% improved within 3 days</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 evanescent facial red spot</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B20" ref-type="bibr">20</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Li et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">China</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Randomized, controlled study</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">53</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">51</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">51.9% improved within 28 days</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">41.1% improved within 28 days</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">2 adverse events within hours after transfusion</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">[<xref rid="B28" ref-type="bibr">28</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Perotti et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1">Italy</td><td valign="top" align="center" rowspan="1" colspan="1">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6.5% died within 7 days</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5 serious adverse events</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B26" ref-type="bibr">26</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Salazar et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">US</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">25</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">76% improved within 14 days</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">None</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">[<xref rid="B25" ref-type="bibr">25</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Shen et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1">China</td><td valign="top" align="center" rowspan="1" colspan="1">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100% improved</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B21" ref-type="bibr">21</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Zeng et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">China</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">6</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">15</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">83% died</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">93% died</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">None</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(227,223,239)">[<xref rid="B24" ref-type="bibr">24</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhang et al., 2020</td><td valign="top" align="center" rowspan="1" colspan="1">China</td><td valign="top" align="center" rowspan="1" colspan="1">Nonrandomized, non-controlled study</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100% improved</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B22" ref-type="bibr">22</xref>]</td></tr></tbody></table></alternatives><table-wrap-foot><p>COVID-19, coronavirus disease 2019.</p></table-wrap-foot></table-wrap><p>Although a recent systematic review showed uncertainty regarding the effectiveness of convalescent plasma for individuals with COVID-19 [<xref rid="B29" ref-type="bibr">29</xref>], ongoing studies including randomized controlled trials will provide further evidence of the effectiveness and safety of convalescent plasma therapy for COVID-19.</p></sec><sec sec-type="other4"><title>Safety</title><p>There are several concerns about the use of convalescent plasma therapy for COVID-19 patients. Transfusion of plasma may cause transfusion-related adverse events, including minor adverse events such as fever, nausea, allergic reactions, transmission of blood-borne pathogens, and some severe adverse events such as transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and antibody-dependent enhancement (ADE) [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B30" ref-type="bibr">30</xref>].</p><p>TACO and TRALI are the leading causes of transfusion-related fatalities, and specific therapies are unavailable [<xref rid="B31" ref-type="bibr">31</xref>]. TACO and TRALI are syndromes of acute respiratory distress that occur within 6 hours of blood transfusion. The pathophysiology of both syndromes is not fully understood. In TACO, cardiac or renal impairment and positive fluid balance may precede circulatory overload. TRALI often presents as bilateral pulmonary edema with little evidence of circulatory overload. TRALI may be caused by preceding inflammation, antileukocyte antibodies, and biological response modifiers. Because COVID-19 itself can induce lung injury, the underlying lung injury associated with COVID-19 further complicates the differential diagnosis of TACO and TRALI, and may increase the risk of TACO and TRALI in critically ill patients.</p><p>ADE may occur when antibodies to the virus fail to efficiently neutralize the virus. Previous studies showed that the binding of virions to non-neutralizing or sub-neutralizing antibodies could lead to more efficient viral uptake into the target cell in Fc&#x003b3; receptor or through complement-mediated mechanisms, leading to enhanced viral replication [<xref rid="B32" ref-type="bibr">32</xref><xref rid="B33" ref-type="bibr">33</xref>]. ADE has been reported for various viral diseases including dengue, Zika, influenza, and respiratory syncytial virus infection. The ADE phenomenon has been demonstrated for SARS-CoV-1 using in vitro and animal models [<xref rid="B34" ref-type="bibr">34</xref>]. However, to date, there has been no evidence of ADE in reported cases and clinical trials on coronaviruses [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref><xref rid="B28" ref-type="bibr">28</xref>].</p><p>A United States (US) study of 5,000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, provided safety data on convalescent plasma therapy [<xref rid="B30" ref-type="bibr">30</xref>]. The incidence of all serious adverse events (SAEs) in the first four hours after transfusion was &#x0003c;1%, including a 0.3% mortality rate. Of the 36 reported SAEs, 25 were assessed as possibly or definitely transfusion related, including mortality (4 cases), TACO (7 cases), TRALI (11 cases), and severe allergic transfusion reactions (3 cases). However, only 2 (of 36) SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The study suggested that convalescent plasma therapy for hospitalized patients with COVID-19 was relatively safe.</p></sec><sec sec-type="other5"><title>Patient and donor eligibility</title><p>Most patients with COVID-19 have mild disease and recover with conservative treatment only. Clinical studies on convalescent plasma therapy for COVID-19 have been conducted in patients with severe or life-threatening disease.</p><p>According to the US Food and Drug Administration (FDA) guidelines, investigators in the US wishing to study the use of convalescent plasma in a clinical trial should submit requests to the FDA for investigational use under the traditional investigational new drug (IND) regulatory pathway [<xref rid="B35" ref-type="bibr">35</xref>]. The suggested patient eligibility criteria are as follows: (1) Laboratory confirmed COVID-19; (2) severe or immediately life-threatening disease; and (3) Informed consent provided by the patient or a healthcare proxy.</p><p>The US FDA also provide suggested donor eligibility criteria which stipulate that donors should satisfy the following conditions:</p><list list-type="simple" id="L1"><list-item><p>(1) Evidence of COVID-19 documented by a laboratory test either by a diagnostic test (<italic>e.g.</italic>, nasopharyngeal swab) at the time of illness or a positive serological test for SARS-CoV-2 antibodies after recovery, if prior diagnostic testing was not performed at the time that COVID-19 was suspected.</p></list-item><list-item><p>(2) Either one of the following (i) Complete resolution of symptoms at least 28 days prior to donation; or (ii) Complete resolution of symptoms at least 14 days prior to donation, and negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood.</p></list-item><list-item><p>(3) Male donors, or female donors who have not been pregnant, or female donors who have been tested since their most recent pregnancy and results were interpreted as negative for human leukocyte antigen (HLA) antibodies.</p></list-item><list-item><p>(4) SARS-CoV-2 neutralizing antibody titers, if available (when measurement of neutralizing antibody titers is available, the US FDA recommends neutralizing antibody titers of at least 1:160. A titer of 1:80 may be considered acceptable if an alternative matched unit is not available. When measurement of neutralizing antibody titers is not available, it is suggested that a retention sample from the convalescent plasma donation be stored so that the antibody titers can be determined at a later date.</p></list-item></list><p>The Korea Centers for Disease Control (KCDC) has also developed donor eligibility criteria as detailed below [<xref rid="B36" ref-type="bibr">36</xref>]:</p><list list-type="simple" id="L2"><list-item><p>(1) An individual who has recovered from COVID-19 can donate plasma at least 14 days after being cured of COVID-19. Negative results of real-time reverse transcription polymerase chain reaction for SARS-CoV-2 using a respiratory specimen should be confirmed if the plasma collection is performed less than 28 days after the donor has been cured of COVID-19. Infectious disease specialists and laboratory medicine specialists should confirm that the donor is completely cured of COVID-19 at the point of plasma collection.</p></list-item><list-item><p>(2) Before plasma collection, the donor's body weight, medical history, social history, physical examination, and laboratory tests must be evaluated to determine whether the individual is suitable to serve as a plasma donor. The minimum standard for age (17 to 69 years old, donors over 65 years of age who have experience of blood donation from 60 to 64 years old), body weight (50 kg or more for men, 45 kg or more for women), and hemoglobin level 12 g/dL or more) should be met.</p></list-item><list-item><p>(3) A repeat donation of plasma can be performed 14 days after apheresis if the doctor confirms that the health condition of the donor is suitable for a repeat donation of plasma.</p></list-item><list-item><p>(4) Other donor screening criteria, blood collection procedures, donor safety matters, and handling of side effects should be in accordance with the current blood management laws and guidelines for general blood management.</p></list-item><list-item><p>(5) Pregnant women are not suitable to serve as plasma donors because of the high probability of TRALI due to anti-HLA antibodies.</p></list-item></list></sec><sec sec-type="other6"><title>Measuring neutralizing antibody titers in convalescent plasma</title><p>Some patients who recover from viral diseases may not have high titers of neutralizing antibodies, which are crucial for the effectiveness of convalescent plasma therapy [<xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref>]. A study showed that virus-specific IgG levels in asymptomatic COVID-19 patients were significantly lower than those in symptomatic patients in the acute phase [<xref rid="B37" ref-type="bibr">37</xref>]. Of asymptomatic individuals, 93.3% and 81.1% had reductions in IgG and neutralizing antibody levels, respectively, during the early convalescent phase, as compared to 96.8% and 62.2% of symptomatic patients, respectively. Forty percent of asymptomatic individuals, and 12.9% of symptomatic individuals, became seronegative for IgG in the early convalescent phase. Another study showed that SARS-CoV-2-specific neutralizing antibody titers were low for the first 7 &#x02013; 10 days after symptom onset and increased after 2 &#x02013; 3 weeks [<xref rid="B38" ref-type="bibr">38</xref>]. The median peak time for neutralizing antibodies was 33 days after symptom onset. The titers in 93&#x000b7;3% of the patients declined gradually over the 3-month study period. Another study evaluated serological reactivity in plasma from 436 convalescent plasma donors with a history of disease compatible with COVID-19 in England [<xref rid="B39" ref-type="bibr">39</xref>]. The study showed that antibody levels declined over 3 months following the diagnosis.</p><p>Because historical experience of the use of convalescent plasma therapy suggests that the neutralizing activity may correlate with the efficacy of convalescent plasma, the measurement of SARS-CoV-2 neutralizing antibody titers should be considered, if available. However, laboratory methods for evaluating neutralizing antibody titers, such as the PRNT, microneutralization assay, and pseudovirus neutralization assay, are not routinely performed in hospital settings. However, as several reports suggest that SARS-CoV-2 specific IgG titers correlate with neutralizing antibody titers [<xref rid="B38" ref-type="bibr">38</xref><xref rid="B40" ref-type="bibr">40</xref>], the SARS-CoV-2-specific IgG titer should be measured in the convalescent plasma.</p></sec><sec sec-type="other7"><title>System development for convalescent plasma therapy</title><p>To perform convalescent plasma therapy for COVID-19, development of a system with an adequate infrastructure is required. A population of donors who have recovered from the disease and can donate convalescent serum need to be recruited. Blood banking facilities to process apheresis are necessary. Essential assays, including serological assays to detect SARS-CoV-2 antibodies in serum, and virological assays to measure viral neutralization, should be performed. To perform the assays for neutralization antibodies, the necessary laboratory support to perform these assays should be implemented. Protocols for safe collection and use of convalescent plasma should be developed. Clinical trials to assess the efficacy, safety, and immunologic responses should be combined with clinical use. Regulatory review and approval should be performed in a timely manner. Pharmaceutical companies should try to develop highly purified preparations containing a high titer of neutralizing antibodies against SARS-CoV-2, which is preferable to convalescent plasma. The preparation may be safer and have higher neutralization activity; however, the development of the hyper-immunoglobulin preparation takes many months.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>With historical precedents and recent clinical studies, convalescent plasma therapy should be considered as a candidate intervention for COVID-19, given the limited evidence of effectiveness of antiviral agents and the lack of a vaccine. A system to secure safe collection and use of convalescent plasma should be developed as a response to the pandemic. Further scientific studies on the safety and effectiveness of convalescent plasma therapy should be explored through clinical trials that can be established concurrently with the clinical use of convalescent plasma therapy.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> No conflicts of interest.</p></fn><fn fn-type="con"><p><bold>Author Contributions:</bold>
<list list-type="simple"><list-item><p><bold>Conceptualization:</bold> JYC.</p></list-item><list-item><p><bold>Data curation:</bold> JYC.</p></list-item><list-item><p><bold>Formal analysis:</bold> JYC.</p></list-item><list-item><p><bold>Funding acquisition:</bold> JYC.</p></list-item><list-item><p><bold>Investigation:</bold> JYC.</p></list-item><list-item><p><bold>Methodology:</bold> JYC.</p></list-item><list-item><p><bold>Project administration:</bold> JYC.</p></list-item><list-item><p><bold>Resources:</bold> JYC.</p></list-item><list-item><p><bold>Software:</bold> JYC.</p></list-item><list-item><p><bold>Supervision:</bold> JYC.</p></list-item><list-item><p><bold>Validation:</bold> JYC.</p></list-item><list-item><p><bold>Visualization:</bold> JYC.</p></list-item><list-item><p><bold>Writing - original draft:</bold> JYC.</p></list-item><list-item><p><bold>Writing - review &#x00026; editing:</bold> JYC.</p></list-item></list>
</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="webpage"><collab>World Health Organization (WHO)</collab><source>Coronavirus disease (COVID-19) pandemic</source><date-in-citation content-type="access-date">Accessed 3 August 2020</date-in-citation><comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>CL</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>LJ</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Chen</surname><given-names>RC</given-names></name><name><surname>Tang</surname><given-names>CL</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Liang</surname><given-names>ZJ</given-names></name><name><surname>Peng</surname><given-names>YX</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>YH</given-names></name><name><surname>Peng</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>ZJ</given-names></name><name><surname>Qiu</surname><given-names>SQ</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>CJ</given-names></name><name><surname>Zhu</surname><given-names>SY</given-names></name><name><surname>Zhong</surname><given-names>NS</given-names></name></person-group><collab>China Medical Treatment Expert Group for Covid-19</collab><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Jung</surname><given-names>SI</given-names></name></person-group><article-title>Age-related morbidity and mortality among patients with COVID-19</article-title><source>Infect Chemother</source><year>2020</year><volume>52</volume><fpage>154</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">32537961</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Huh</surname><given-names>K</given-names></name><name><surname>Heo</surname><given-names>JY</given-names></name><name><surname>Joo</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Seo</surname><given-names>YB</given-names></name><name><surname>Yoon</surname><given-names>YK</given-names></name><name><surname>Ku</surname><given-names>NS</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Peck</surname><given-names>KR</given-names></name><name><surname>Yeom</surname><given-names>JS</given-names></name></person-group><article-title>Interim guidelines on antiviral therapy for COVID-19</article-title><source>Infect Chemother</source><year>2020</year><volume>52</volume><fpage>281</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">32342676</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Tomashek</surname><given-names>KM</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Zingman</surname><given-names>BS</given-names></name><name><surname>Kalil</surname><given-names>AC</given-names></name><name><surname>Hohmann</surname><given-names>E</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Luetkemeyer</surname><given-names>A</given-names></name><name><surname>Kline</surname><given-names>S</given-names></name><name><surname>Lopez de Castilla</surname><given-names>D</given-names></name><name><surname>Finberg</surname><given-names>RW</given-names></name><name><surname>Dierberg</surname><given-names>K</given-names></name><name><surname>Tapson</surname><given-names>V</given-names></name><name><surname>Hsieh</surname><given-names>L</given-names></name><name><surname>Patterson</surname><given-names>TF</given-names></name><name><surname>Paredes</surname><given-names>R</given-names></name><name><surname>Sweeney</surname><given-names>DA</given-names></name><name><surname>Short</surname><given-names>WR</given-names></name><name><surname>Touloumi</surname><given-names>G</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Ohmagari</surname><given-names>N</given-names></name><name><surname>Oh</surname><given-names>MD</given-names></name><name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name><name><surname>Benfield</surname><given-names>T</given-names></name><name><surname>F&#x000e4;tkenheuer</surname><given-names>G</given-names></name><name><surname>Kortepeter</surname><given-names>MG</given-names></name><name><surname>Atmar</surname><given-names>RL</given-names></name><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>Lundgren</surname><given-names>J</given-names></name><name><surname>Babiker</surname><given-names>AG</given-names></name><name><surname>Pett</surname><given-names>S</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Burgess</surname><given-names>TH</given-names></name><name><surname>Bonnett</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Makowski</surname><given-names>M</given-names></name><name><surname>Osinusi</surname><given-names>A</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name></person-group><collab>ACTT-1 Study Group Members</collab><article-title>Remdesivir for the treatment of Covid-19 - preliminary report</article-title><source>N Engl J Med</source><year>2020</year><elocation-id>NEJMoa2007764</elocation-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><collab>RECOVERY Collaborative Group</collab><person-group person-group-type="author"><name><surname>Horby</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Emberson</surname><given-names>JR</given-names></name><name><surname>Mafham</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>JL</given-names></name><name><surname>Linsell</surname><given-names>L</given-names></name><name><surname>Staplin</surname><given-names>N</given-names></name><name><surname>Brightling</surname><given-names>C</given-names></name><name><surname>Ustianowski</surname><given-names>A</given-names></name><name><surname>Elmahi</surname><given-names>E</given-names></name><name><surname>Prudon</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Felton</surname><given-names>T</given-names></name><name><surname>Chadwick</surname><given-names>D</given-names></name><name><surname>Rege</surname><given-names>K</given-names></name><name><surname>Fegan</surname><given-names>C</given-names></name><name><surname>Chappell</surname><given-names>LC</given-names></name><name><surname>Faust</surname><given-names>SN</given-names></name><name><surname>Jaki</surname><given-names>T</given-names></name><name><surname>Jeffery</surname><given-names>K</given-names></name><name><surname>Montgomery</surname><given-names>A</given-names></name><name><surname>Rowan</surname><given-names>K</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Haynes</surname><given-names>R</given-names></name><name><surname>Landray</surname><given-names>MJ</given-names></name></person-group><article-title>Dexamethasone in hospitalized patients with Covid-19 - preliminary report</article-title><source>N Engl J Med</source><year>2020</year><elocation-id>NEJMoa2021436</elocation-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Cleary</surname><given-names>P</given-names></name><name><surname>Khaw</surname><given-names>FM</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Makki</surname><given-names>S</given-names></name><name><surname>Rooney</surname><given-names>KD</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>JS</given-names></name><name><surname>Beck</surname><given-names>CR</given-names></name></person-group><collab>Convalescent Plasma Study Group</collab><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J Infect Dis</source><year>2015</year><volume>211</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Monsalve</surname><given-names>DM</given-names></name><name><surname>Pacheco</surname><given-names>Y</given-names></name><name><surname>Acosta-Ampudia</surname><given-names>Y</given-names></name><name><surname>Ram&#x000ed;rez-Santana</surname><given-names>C</given-names></name><name><surname>Ansari</surname><given-names>AA</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name><name><surname>Anaya</surname><given-names>JM</given-names></name></person-group><article-title>Ebola virus disease: An emerging and re-emerging viral threat</article-title><source>J Autoimmun</source><year>2020</year><volume>106</volume><elocation-id>102375</elocation-id><pub-id pub-id-type="pmid">31806422</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planitzer</surname><given-names>CB</given-names></name><name><surname>Modrof</surname><given-names>J</given-names></name><name><surname>Kreil</surname><given-names>TR</given-names></name></person-group><article-title>West Nile virus neutralization by US plasma-derived immunoglobulin products</article-title><source>J Infect Dis</source><year>2007</year><volume>196</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">17597458</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casadevall</surname><given-names>A</given-names></name><name><surname>Pirofski</surname><given-names>LA</given-names></name></person-group><article-title>The convalescent sera option for containing COVID-19</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><fpage>1545</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">32167489</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>TC</given-names></name><name><surname>Kilbane</surname><given-names>EM</given-names></name><name><surname>Jackson</surname><given-names>JL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">16940336</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>WW</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Watt</surname><given-names>CL</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Lai</surname><given-names>KY</given-names></name><name><surname>Koo</surname><given-names>CK</given-names></name><name><surname>Buckley</surname><given-names>T</given-names></name><name><surname>Chow</surname><given-names>FL</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Chan</surname><given-names>HS</given-names></name><name><surname>Ching</surname><given-names>CK</given-names></name><name><surname>Tang</surname><given-names>BS</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>IW</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>CK</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">21248066</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahr</surname><given-names>F</given-names></name><name><surname>Ansumana</surname><given-names>R</given-names></name><name><surname>Massaquoi</surname><given-names>TA</given-names></name><name><surname>Idriss</surname><given-names>BR</given-names></name><name><surname>Sesay</surname><given-names>FR</given-names></name><name><surname>Lamin</surname><given-names>JM</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Nicol</surname><given-names>S</given-names></name><name><surname>Conton</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>W</given-names></name><name><surname>Abiri</surname><given-names>OT</given-names></name><name><surname>Kargbo</surname><given-names>O</given-names></name><name><surname>Kamara</surname><given-names>P</given-names></name><name><surname>Goba</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>JB</given-names></name><name><surname>Gevao</surname><given-names>SM</given-names></name></person-group><article-title>Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone</article-title><source>J Infect</source><year>2017</year><volume>74</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">27867062</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Griensven</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>T</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Baize</surname><given-names>S</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Raoul</surname><given-names>H</given-names></name><name><surname>Magassouba</surname><given-names>N</given-names></name><name><surname>Antierens</surname><given-names>A</given-names></name><name><surname>Lomas</surname><given-names>C</given-names></name><name><surname>Faye</surname><given-names>O</given-names></name><name><surname>Sall</surname><given-names>AA</given-names></name><name><surname>Fransen</surname><given-names>K</given-names></name><name><surname>Buyze</surname><given-names>J</given-names></name><name><surname>Ravinetto</surname><given-names>R</given-names></name><name><surname>Tiberghien</surname><given-names>P</given-names></name><name><surname>Claeys</surname><given-names>Y</given-names></name><name><surname>De Crop</surname><given-names>M</given-names></name><name><surname>Lynen</surname><given-names>L</given-names></name><name><surname>Bah</surname><given-names>EI</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Delamou</surname><given-names>A</given-names></name><name><surname>De Weggheleire</surname><given-names>A</given-names></name><name><surname>Haba</surname><given-names>N</given-names></name></person-group><collab>Ebola-Tx Consortium</collab><article-title>Evaluation of convalescent plasma for Ebola virus disease in Guinea</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26735992</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Soo</surname><given-names>YO</given-names></name><name><surname>Wong</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>KC</given-names></name><name><surname>Leung</surname><given-names>CB</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2005</year><volume>24</volume><fpage>44</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15616839</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>JH</given-names></name><name><surname>Seok</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><name><surname>Ha</surname><given-names>YE</given-names></name><name><surname>Baek</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Chung</surname><given-names>CR</given-names></name><name><surname>Kang</surname><given-names>ES</given-names></name><name><surname>Cho</surname><given-names>D</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>CI</given-names></name><name><surname>Chung</surname><given-names>DR</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Peck</surname><given-names>KR</given-names></name></person-group><article-title>Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience</article-title><source>Antivir Ther</source><year>2018</year><volume>23</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">29923831</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>K</given-names></name><name><surname>Krishnasamy</surname><given-names>N</given-names></name><name><surname>Rangarajan</surname><given-names>J</given-names></name><name><surname>Rathinam</surname><given-names>J</given-names></name><name><surname>Natarajan</surname><given-names>M</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name></person-group><article-title>Convalescent plasma transfusion for the treatment of COVID-19: Systematic review</article-title><source>J Med Virol</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>Y</given-names></name><name><surname>Monsalve</surname><given-names>DM</given-names></name><name><surname>Acosta-Ampudia</surname><given-names>Y</given-names></name><name><surname>Camacho</surname><given-names>B</given-names></name><name><surname>Gallo</surname><given-names>JE</given-names></name><name><surname>Rojas-Villarraga</surname><given-names>A</given-names></name><name><surname>Ram&#x000ed;rez-Santana</surname><given-names>C</given-names></name><name><surname>D&#x000ed;az-Coronado</surname><given-names>JC</given-names></name><name><surname>Manrique</surname><given-names>R</given-names></name><name><surname>Mantilla</surname><given-names>RD</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Anaya</surname><given-names>JM</given-names></name></person-group><article-title>Convalescent plasma in Covid-19: Possible mechanisms of action</article-title><source>Autoimmun Rev</source><year>2020</year><volume>19</volume><elocation-id>102554</elocation-id><pub-id pub-id-type="pmid">32380316</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garraud</surname><given-names>O</given-names></name><name><surname>Heshmati</surname><given-names>F</given-names></name><name><surname>Pozzetto</surname><given-names>B</given-names></name><name><surname>Lefrere</surname><given-names>F</given-names></name><name><surname>Girot</surname><given-names>R</given-names></name><name><surname>Saillol</surname><given-names>A</given-names></name><name><surname>Laperche</surname><given-names>S</given-names></name></person-group><article-title>Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow</article-title><source>Transfus Clin Biol</source><year>2016</year><volume>23</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">26775794</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Qing</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">32219428</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection</article-title><source>Chest</source><year>2020</year><volume>158</volume><fpage>e9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">32243945</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JY</given-names></name><name><surname>Sohn</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Hyun</surname><given-names>JH</given-names></name><name><surname>Baek</surname><given-names>YJ</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Ku</surname><given-names>NS</given-names></name><name><surname>Yeom</surname><given-names>JS</given-names></name><name><surname>Roh</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>MY</given-names></name><name><surname>Chin</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Yong</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>HO</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name></person-group><article-title>Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea</article-title><source>J Korean Med Sci</source><year>2020</year><volume>35</volume><elocation-id>e149</elocation-id><pub-id pub-id-type="pmid">32281317</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>QL</given-names></name><name><surname>Yu</surname><given-names>ZJ</given-names></name><name><surname>Gou</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>GM</given-names></name><name><surname>Ma</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>GF</given-names></name><name><surname>Xu</surname><given-names>JH</given-names></name><name><surname>Lin</surname><given-names>WB</given-names></name><name><surname>Cui</surname><given-names>GL</given-names></name><name><surname>Zhang</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>ZS</given-names></name><name><surname>Zhang</surname><given-names>ZH</given-names></name><name><surname>Liu</surname><given-names>ZS</given-names></name></person-group><article-title>Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019</article-title><source>J Infect Dis</source><year>2020</year><volume>222</volume><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">32348485</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>E</given-names></name><name><surname>Perez</surname><given-names>KK</given-names></name><name><surname>Ashraf</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Castillo</surname><given-names>B</given-names></name><name><surname>Christensen</surname><given-names>PA</given-names></name><name><surname>Eubank</surname><given-names>T</given-names></name><name><surname>Bernard</surname><given-names>DW</given-names></name><name><surname>Eagar</surname><given-names>TN</given-names></name><name><surname>Long</surname><given-names>SW</given-names></name><name><surname>Subedi</surname><given-names>S</given-names></name><name><surname>Olsen</surname><given-names>RJ</given-names></name><name><surname>Leveque</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>MR</given-names></name><name><surname>Dey</surname><given-names>M</given-names></name><name><surname>Chavez-East</surname><given-names>C</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Shehabeldin</surname><given-names>A</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>K</given-names></name><name><surname>Masud</surname><given-names>F</given-names></name><name><surname>Talley</surname><given-names>C</given-names></name><name><surname>Dlouhy</surname><given-names>KG</given-names></name><name><surname>Lopez</surname><given-names>BV</given-names></name><name><surname>Hampton</surname><given-names>C</given-names></name><name><surname>Lavinder</surname><given-names>J</given-names></name><name><surname>Gollihar</surname><given-names>JD</given-names></name><name><surname>Maranhao</surname><given-names>AC</given-names></name><name><surname>Ippolito</surname><given-names>GC</given-names></name><name><surname>Saavedra</surname><given-names>MO</given-names></name><name><surname>Cantu</surname><given-names>CC</given-names></name><name><surname>Yerramilli</surname><given-names>P</given-names></name><name><surname>Pruitt</surname><given-names>L</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name></person-group><article-title>Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma</article-title><source>Am J Pathol</source><year>2020</year><volume>190</volume><fpage>1680</fpage><lpage>1690</lpage><pub-id pub-id-type="pmid">32473109</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perotti</surname><given-names>C</given-names></name><name><surname>Baldanti</surname><given-names>F</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name><name><surname>Del Fante</surname><given-names>C</given-names></name><name><surname>Seminari</surname><given-names>E</given-names></name><name><surname>Casari</surname><given-names>S</given-names></name><name><surname>Percivalle</surname><given-names>E</given-names></name><name><surname>Glingani</surname><given-names>C</given-names></name><name><surname>Musella</surname><given-names>V</given-names></name><name><surname>Belliato</surname><given-names>M</given-names></name><name><surname>Garuti</surname><given-names>M</given-names></name><name><surname>Meloni</surname><given-names>F</given-names></name><name><surname>Frigato</surname><given-names>M</given-names></name><name><surname>Di Sabatino</surname><given-names>A</given-names></name><name><surname>Klersy</surname><given-names>C</given-names></name><name><surname>De Donno</surname><given-names>G</given-names></name><name><surname>Franchini</surname><given-names>M</given-names></name></person-group><article-title>Covid-19 plasma task force. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial</article-title><source>Haematologica</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abolghasemi</surname><given-names>H</given-names></name><name><surname>Eshghi</surname><given-names>P</given-names></name><name><surname>Cheraghali</surname><given-names>AM</given-names></name><name><surname>Imani Fooladi</surname><given-names>AA</given-names></name><name><surname>Bolouki Moghaddam</surname><given-names>F</given-names></name><name><surname>Imanizadeh</surname><given-names>S</given-names></name><name><surname>Moeini Maleki</surname><given-names>M</given-names></name><name><surname>Ranjkesh</surname><given-names>M</given-names></name><name><surname>Rezapour</surname><given-names>M</given-names></name><name><surname>Bahramifar</surname><given-names>A</given-names></name><name><surname>Einollahi</surname><given-names>B</given-names></name><name><surname>Hosseini</surname><given-names>MJ</given-names></name><name><surname>Jafari</surname><given-names>NJ</given-names></name><name><surname>Nikpouraghdam</surname><given-names>M</given-names></name><name><surname>Sadri</surname><given-names>N</given-names></name><name><surname>Tazik</surname><given-names>M</given-names></name><name><surname>Sali</surname><given-names>S</given-names></name><name><surname>Okati</surname><given-names>S</given-names></name><name><surname>Askari</surname><given-names>E</given-names></name><name><surname>Tabarsi</surname><given-names>P</given-names></name><name><surname>Aslani</surname><given-names>J</given-names></name><name><surname>Sharifipour</surname><given-names>E</given-names></name><name><surname>Jarahzadeh</surname><given-names>MH</given-names></name><name><surname>Khodakarim</surname><given-names>N</given-names></name><name><surname>Salesi</surname><given-names>M</given-names></name><name><surname>Jafari</surname><given-names>R</given-names></name><name><surname>Shahverdi</surname><given-names>S</given-names></name></person-group><article-title>Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study</article-title><source>Transfus Apher Sci</source><edition>2020</edition><comment>[Epub ahaed of print]</comment></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Tao</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Xiong</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Man</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial</article-title><source>JAMA</source><year>2020</year><volume>324</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piechotta</surname><given-names>V</given-names></name><name><surname>Chai</surname><given-names>KL</given-names></name><name><surname>Valk</surname><given-names>SJ</given-names></name><name><surname>Doree</surname><given-names>C</given-names></name><name><surname>Monsef</surname><given-names>I</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Lamikanra</surname><given-names>A</given-names></name><name><surname>Kimber</surname><given-names>C</given-names></name><name><surname>McQuilten</surname><given-names>Z</given-names></name><name><surname>So-Osman</surname><given-names>C</given-names></name><name><surname>Estcourt</surname><given-names>LJ</given-names></name><name><surname>Skoetz</surname><given-names>N</given-names></name></person-group><article-title>Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review</article-title><source>Cochrane Database Syst Rev</source><year>2020</year><volume>7</volume><elocation-id>CD013600</elocation-id><pub-id pub-id-type="pmid">32648959</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyner</surname><given-names>MJ</given-names></name><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Senefeld</surname><given-names>JW</given-names></name><name><surname>Bruno</surname><given-names>KA</given-names></name><name><surname>Klassen</surname><given-names>SA</given-names></name><name><surname>Carter</surname><given-names>RE</given-names></name><name><surname>Klompas</surname><given-names>AM</given-names></name><name><surname>Wiggins</surname><given-names>CC</given-names></name><name><surname>Shepherd</surname><given-names>JR</given-names></name><name><surname>Rea</surname><given-names>RF</given-names></name><name><surname>Whelan</surname><given-names>ER</given-names></name><name><surname>Clayburn</surname><given-names>AJ</given-names></name><name><surname>Spiegel</surname><given-names>MR</given-names></name><name><surname>Johnson</surname><given-names>PW</given-names></name><name><surname>Lesser</surname><given-names>ER</given-names></name><name><surname>Baker</surname><given-names>SE</given-names></name><name><surname>Larson</surname><given-names>KF</given-names></name><name><surname>Ripoll</surname><given-names>JG</given-names></name><name><surname>Andersen</surname><given-names>KJ</given-names></name><name><surname>Hodge</surname><given-names>DO</given-names></name><name><surname>Kunze</surname><given-names>KL</given-names></name><name><surname>Buras</surname><given-names>MR</given-names></name><name><surname>Vogt</surname><given-names>MN</given-names></name><name><surname>Herasevich</surname><given-names>V</given-names></name><name><surname>Dennis</surname><given-names>JJ</given-names></name><name><surname>Regimbal</surname><given-names>RJ</given-names></name><name><surname>Bauer</surname><given-names>PR</given-names></name><name><surname>Blair</surname><given-names>JE</given-names></name><name><surname>Van Buskirk</surname><given-names>CM</given-names></name><name><surname>Winters</surname><given-names>JL</given-names></name><name><surname>Stubbs</surname><given-names>JR</given-names></name><name><surname>Paneth</surname><given-names>NS</given-names></name><name><surname>Verdun</surname><given-names>NC</given-names></name><name><surname>Marks</surname><given-names>P</given-names></name><name><surname>Casadevall</surname><given-names>A</given-names></name></person-group><article-title>Early safety indicators of COVID-19 convalescent plasma in 5,000 patients</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><fpage>4791</fpage><lpage>4797</lpage><pub-id pub-id-type="pmid">32525844</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>JW</given-names></name><name><surname>Rebetz</surname><given-names>J</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name></person-group><article-title>Transfusion-associated circulatory overload and transfusion-related acute lung injury</article-title><source>Blood</source><year>2019</year><volume>133</volume><fpage>1840</fpage><lpage>1853</lpage><pub-id pub-id-type="pmid">30808638</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smatti</surname><given-names>MK</given-names></name><name><surname>Al Thani</surname><given-names>AA</given-names></name><name><surname>Yassine</surname><given-names>HM</given-names></name></person-group><article-title>Viral-induced enhanced disease illness</article-title><source>Front Microbiol</source><year>2018</year><volume>9</volume><fpage>2991</fpage><pub-id pub-id-type="pmid">30568643</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>J Virol</source><year>2020</year><volume>94</volume><fpage>e02015</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31826992</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kuwahara</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Morioka</surname><given-names>H</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates</article-title><source>ACS Infect Dis</source><year>2016</year><volume>2</volume><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">27627203</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="webpage"><collab>Food and Drug Administration (FDA)</collab><source>Recommendations for investigational COVID-19 convalescent plasma</source><date-in-citation content-type="access-date">Accessed 3 August 2020</date-in-citation><comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</ext-link></comment></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="webpage"><collab>Korea Centers for Disease Control and Prevention (KCDC)</collab><source>Guidelines for collecting convalescent plasma of COVID-19</source><date-in-citation content-type="access-date">Accessed 3 August 2020</date-in-citation><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.nih.go.kr/board/board.es?mid=a20507020000&#x00026;bid=0019&#x00026;act=view&#x00026;list_no=366816&#x00026;tag=&#x00026;nPage=1">http://www.nih.go.kr/board/board.es?mid=a20507020000&#x00026;bid=0019&#x00026;act=view&#x00026;list_no=366816&#x00026;tag=&#x00026;nPage=1</ext-link></comment></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>QX</given-names></name><name><surname>Tang</surname><given-names>XJ</given-names></name><name><surname>Shi</surname><given-names>QL</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>HJ</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>FJ</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Qiu</surname><given-names>JF</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>AL</given-names></name></person-group><article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><fpage>1200</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">32555424</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Long</surname><given-names>QX</given-names></name><name><surname>Deng</surname><given-names>HJ</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>QZ</given-names></name><name><surname>Zhang</surname><given-names>GJ</given-names></name><name><surname>He</surname><given-names>CL</given-names></name><name><surname>Huang</surname><given-names>LY</given-names></name><name><surname>Hu</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>AL</given-names></name></person-group><article-title>Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection</article-title><source>Clin Infect Dis</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvala</surname><given-names>H</given-names></name><name><surname>Mehew</surname><given-names>J</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Dicks</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>N</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Gopal</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>DJ</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><collab>NHS Blood and Transplant Convalescent Plasma Testing Group</collab><article-title>Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020</article-title><source>Euro Surveill</source><year>2020</year><volume>25</volume><elocation-id>2001260</elocation-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juno</surname><given-names>JA</given-names></name><name><surname>Tan</surname><given-names>HX</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Reynaldi</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>HG</given-names></name><name><surname>Wragg</surname><given-names>K</given-names></name><name><surname>Esterbauer</surname><given-names>R</given-names></name><name><surname>Kent</surname><given-names>HE</given-names></name><name><surname>Batten</surname><given-names>CJ</given-names></name><name><surname>Mordant</surname><given-names>FL</given-names></name><name><surname>Gherardin</surname><given-names>NA</given-names></name><name><surname>Pymm</surname><given-names>P</given-names></name><name><surname>Dietrich</surname><given-names>MH</given-names></name><name><surname>Scott</surname><given-names>NE</given-names></name><name><surname>Tham</surname><given-names>WH</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Davenport</surname><given-names>MP</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name></person-group><article-title>Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19</article-title><source>Nat Med</source><year>2020</year><comment>Epub ahead of print</comment></element-citation></ref></ref-list></back></article>